A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Olokizumab Administered Subcutaneously to Subjects With Moderate to Severe Crohn's Disease

The primary purpose of this multi-centre, double blind-study is to evaluate the clinical response of patients with moderate to severe Cohn's Disease (CD) following treatment with different doses and dose regimens of Olokizumab, relative to placebo.

Study Overview

• Status: Withdrawn
• Conditions: Crohn's Disease
• Intervention / Treatment: Drug: Olokizumab (OKZ); Drug: Placebo

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subject is male or female, 18 to 65 years of age at Screening
• Diagnosis of CD (colonic localization) confirmed (at least 12 weeks prior to Screening) by either radiological or endoscopic evidence and/or histological examination
• Colonoscopy performed prior to first study medication administration (Week 0) with evidence of active CD and presence of ulceration but with no clinical suspicion of dysplasia or malignancy (colonoscopy to be performed after informed consent has been received, and all other Screening assessments have been completed)
• Moderately to severely active CD (CDAI score: 220 to 450, inclusive) at Baseline
• Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (either oral/ parenteral /implantable hormonal contraceptives, intrauterine device or barrier and spermicide)

Exclusion Criteria:

• Subject has a diagnosis of Ulcerative Colitis or Indeterminant Colitis as determined by the investigator
• Subject has obstructive strictures with clinical evidence of partial or complete obstruction
• Subject has an active fistula (fistula secreting spontaneously or by gentle pressure)
• Subject has a history of diverticulitis or symptomatic diverticulosis
• Subject has any prior exposure to anti-IL-6 agents (eg, Tocilizumab)
• Female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 24 weeks following the last dose of the study drug
• Subject has a high risk of infection (eg, subjects with leg ulcers, indwelling urinary catheter, persistent or recurrent chest infections, and subjects who are permanently bedridden or wheelchair bound)
• Subject has a concurrent malignancy or a history of malignancy. Subjects who have been successfully treated and who have remained malignancy-free for at least 5 years prior to Screening may be included

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
Experimental: OKZ 120 mg	Drug: Olokizumab (OKZ); Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period: OKZ 120 mg every 2 weeks; OKZ 240 mg every 2 weeks; OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0 1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.; Other Names: CDP6038
Experimental: OKZ 240 mg	Drug: Olokizumab (OKZ); Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period: OKZ 120 mg every 2 weeks; OKZ 240 mg every 2 weeks; OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0 1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.; Other Names: CDP6038
Experimental: OKZ 120 mg with 480 mg loading dose at Week 0	Drug: Olokizumab (OKZ); Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period: OKZ 120 mg every 2 weeks; OKZ 240 mg every 2 weeks; OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0 1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0.; Other Names: CDP6038

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Percentage of subjects with clinical response or remission as measured by the Crohn's Disease Activity Index (CDAI) at Week 8	Week 8

Secondary Outcome Measures

Outcome Measure	Time Frame
Percentage of subjects with clinical response as measured by the Crohn's Disease Activity Index (CDAI) at Week 16	Week 16
Percentage of subjects with clinical remission as measured by the Crohn's Disease Activity Index (CDAI) at Week 16	Week 16
Change from Baseline in the Crohn's Disease Activity Index (CDAI) to Week 16	From Baseline to Week 16
Change from Baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 16	From Baseline to Week 16
Percentage of subjects with Inflammatory Bowel Disease Questionnaire (IBDQ) response at Week 16	Week 16
Percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 16	Week 16

Collaborators and Investigators

• Sponsor: UCB BIOSCIENCES GmbH

Study record dates

Study Major Dates

• Study Start: June 1, 2012
• Primary Completion (Anticipated): August 1, 2013
• Study Completion (Anticipated): August 1, 2013

Study Registration Dates

• First Submitted: July 3, 2012
• First Submitted That Met QC Criteria: July 3, 2012
• First Posted (Estimate): July 9, 2012

Study Record Updates

• Last Update Posted (Estimate): October 30, 2012
• Last Update Submitted That Met QC Criteria: October 29, 2012
• Last Verified: October 1, 2012

More Information

Terms related to this study

• Keywords: Crohn's Disease; Olokizumab; CDAI; IBDQ; CDP6038; OKZ
• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Inflammatory Bowel Diseases; Crohn Disease
• Other Study ID Numbers: CD0001; 2011-002517-11 (EudraCT Number)